Sally Susman - Feb 26, 2022 Form 4 Insider Report for PFIZER INC (PFE)

Role
Executive Vice President
Signature
Susan E. Grant, by power of atty., for Sally Susman
Stock symbol
PFE
Transactions as of
Feb 26, 2022
Transactions value $
-$770,112
Form type
4
Date filed
3/1/2022, 04:55 PM
Previous filing
Feb 25, 2022
Next filing
May 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PFE Common Stock Options Exercise $1.63M +63.6K +58.17% $25.60 173K Feb 26, 2022 Direct F1
transaction PFE Common Stock Tax liability -$895K -18.7K -10.84% $47.72 154K Feb 26, 2022 Direct F2, F3
transaction PFE Common Stock Tax liability -$1.5M -29.7K -19.26% $50.64 124K Feb 26, 2022 Direct F4, F5
holding PFE Common Stock 747 Feb 26, 2022 By Rule 16b-3 Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PFE Stock Appreciation Rights Options Exercise $0 -63.6K -100% $0.00* 0 Feb 26, 2022 Common Stock 63.6K $25.60 Direct
transaction PFE Phantom Stock Units Award $0 +58.6K +271.38% $0.00 80.2K Feb 28, 2022 Common Stock 58.6K Direct F6, F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2 The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F3 Price is the closing price of Pfizer common stock on February 25, 2022.
F4 The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F5 Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
F6 Each unit represents one phantom share of common stock.
F7 The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon) which have been deferred into the Pfizer Inc. Deferred Compensation Plan.
F8 The units, held under the Deferred Compensation Plan, are paid in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.